When does JD Health (6618.HK) report earnings and what matters most?

JD Health reports on **05 Mar 2026**. Investors will focus on revenue mix, online services growth, margin improvement, and management guidance. These items should drive the immediate post-earnings move for 6618.HK stock.

What valuation and metrics should I watch for 6618.HK stock?

Watch **PE 31.83**, **EPS HKD 1.69**, cash per share **HKD 14.02**, and price-to-sales **2.33**. These metrics frame whether earnings justify the current 6618.HK stock price.

How does Meyka AI view the upside for 6618.HK stock?

Meyka AI's yearly forecast is **HKD 77.72**, implying about **49.60% upside** from **HKD 51.95**. The model is a projection, not a guarantee, and assumes normal market conditions.

What are the main risks to 6618.HK stock after earnings?

Main risks include weaker pharmacy sales, regulatory headwinds in China, and margin pressure. A negative guidance update or missed revenue mix targets could push 6618.HK stock lower.

HK Stocks

6618.HK JD Health (HKSE) falls 8.46% pre-market 04 Mar 2026: earnings due 05 Mar may shift outlook

ByHuzaifa Zahoor March 3, 2026March 3, 2026

6618.HK stock is trading at HKD 51.95, down 8.46% in pre-market trade on 04 Mar 2026 as investors position ahead of JD Health’s earnings due 05 Mar 2026. The move follows heavy volume of 11,046,244 shares and reflects short-term profit taking against a one-year gain of 51.55%. The upcoming report will be the first major catalyst this week and could redefine near-term valuation given a trailing PE of 31.83 and EPS of HKD 1.69.